Cyclacel Pharmaceuticals, Inc. Quarterly Other Assets, Current in USD from Q4 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current assets classified as other.
Summary
Cyclacel Pharmaceuticals, Inc. quarterly Other Assets, Current history and growth rate from Q4 2011 to Q2 2024.
  • Cyclacel Pharmaceuticals, Inc. Other Assets, Current for the quarter ending June 30, 2024 was $300K, a 86.3% decline year-over-year.
Other Assets, Current, Quarterly (USD)
Other Assets, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $300K -$1.89M -86.3% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $365K -$230K -38.7% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $341K -$85K -20% Dec 31, 2023 10-Q 2024-08-14
Q3 2023 $1.95M +$1.78M +1047% Sep 30, 2023 10-Q 2023-11-29
Q2 2023 $2.19M +$2.11M +2667% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $595K -$944K -61.3% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $426K +$347K +439% Dec 31, 2022 10-K 2024-03-21
Q3 2022 $170K +$58K +51.8% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $79K -$63K -44.4% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $1.54M +$1.31M +575% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $79K +$13K +19.7% Dec 31, 2021 10-K/A 2023-11-29
Q3 2021 $112K -$28K -20% Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $142K +$38K +36.5% Jun 30, 2021 10-Q 2021-08-12
Q1 2021 $228K -$842K -78.7% Mar 31, 2021 10-Q 2021-05-14
Q4 2020 $66K -$37K -35.9% Dec 31, 2020 10-K 2022-03-30
Q3 2020 $140K +$21K +17.6% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $104K -$132K -55.9% Jun 30, 2020 10-Q 2020-08-13
Q1 2020 $1.07M +$998K +1386% Mar 31, 2020 10-Q 2020-05-12
Q4 2019 $103K -$133K -56.4% Dec 31, 2019 10-K 2021-03-01
Q3 2019 $119K +$37K +45.1% Sep 30, 2019 10-Q 2019-11-13
Q2 2019 $236K +$64K +37.2% Jun 30, 2019 10-Q 2019-08-13
Q1 2019 $72K -$612K -89.5% Mar 31, 2019 10-Q 2019-05-14
Q4 2018 $236K +$130K +123% Dec 31, 2018 10-K 2020-03-05
Q3 2018 $82K -$124K -60.2% Sep 30, 2018 10-Q 2018-11-13
Q2 2018 $172K -$28K -14% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $684K +$547K +399% Mar 31, 2018 10-Q 2018-05-14
Q4 2017 $106K +$65K +159% Dec 31, 2017 10-K 2019-03-28
Q3 2017 $206K -$1.33M -86.6% Sep 30, 2017 10-Q 2017-11-13
Q2 2017 $200K +$180K +900% Jun 30, 2017 10-Q 2017-08-10
Q1 2017 $137K Mar 31, 2017 10-Q 2017-05-12
Q4 2016 $41K -$34K -45.3% Dec 31, 2016 10-K 2018-03-30
Q3 2016 $1.54M +$1.36M +778% Sep 30, 2016 10-Q 2016-11-14
Q2 2016 $20K -$85K -81% Jun 30, 2016 10-Q 2016-08-11
Q4 2015 $75K -$71K -48.6% Dec 31, 2015 10-K 2017-03-31
Q3 2015 $175K -$243K -58.1% Sep 30, 2015 10-Q 2015-11-12
Q2 2015 $105K -$220K -67.7% Jun 30, 2015 10-Q 2015-08-12
Q1 2015 $64K -$419K -86.7% Mar 31, 2015 10-Q 2015-05-12
Q4 2014 $146K -$373K -71.9% Dec 31, 2014 10-K 2016-03-29
Q3 2014 $418K +$364K +674% Sep 30, 2014 10-Q 2014-11-12
Q2 2014 $325K +$280K +622% Jun 30, 2014 10-Q 2014-08-12
Q1 2014 $483K +$476K +6800% Mar 31, 2014 10-Q 2014-05-13
Q4 2013 $519K +$509K +5090% Dec 31, 2013 10-K 2015-03-31
Q3 2013 $54K -$131K -70.8% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 $45K -$68K -60.2% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 $7K Mar 31, 2013 10-Q 2013-05-13
Q4 2012 $10K -$198K -95.2% Dec 31, 2012 10-K 2014-03-26
Q3 2012 $185K Sep 30, 2012 10-Q 2012-11-16
Q2 2012 $113K Jun 30, 2012 10-Q 2012-08-14
Q4 2011 $208K Dec 31, 2011 10-K 2013-04-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.